Mandate

Vinge has advised CELLINK in connection with directed issues of SEK 3 billion

Vinge has advised CELLINK AB (publ) in connection with a directed issue of covertibles of SEK 1.5 billion and a directed issue of B-shares of SEK 1.5 billion, in total SEK 3 billion.

The convertibles and the shares have been offered by way of an accelerated bookbuilding process arranged by Citigroup Global Markets, J.P. Morgan and Carnegie Investment Bank. The convertibles and shares were subscribed for by Swedish and international institutional investors.

Vinge’s team has consisted of Anders Strid, Edin Agic, Hampus Olsson, Linus Adolfsson and Maria Schultzberg (tax). Sullivan & Cromwell has advised Cellink in relation to English and US laws.

Related

Vinge advises HealthCap in conjunction with an investment in Neobiomics

HealthCap is investing in Neobiomics AB, which develops products in the neonatal field. Neobiomics’ flagship product, Proprems, is a probiotic dietary supplement developed for preterm infants.
May 22, 2026

Vinge advises Sveafastigheter in its merger with KlaraBo

Vinge advises Sveafastigheter AB (publ) in its merger with KlaraBo Sverige AB.
May 22, 2026

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026